@davecash75.bsky.social
š¤ 144
š„ 47
š 3
reposted by
Julie Ottoy
5 months ago
š„Recent advances in
#neuroimaging
of
#Alzheimers
disease š§ āØ
dx.doi.org/10.1002/alz....
ā”ļø Valuable resource for both researchers & clinicians! ā”ļø ATNIV biomarkers, staging, connectomics & more ā”ļø Plus: how are sex & country represented in first/last authorship?
@istaart.bsky.social
Neuroimaging PIA
1
29
14
reposted by
Dementia Researcher
7 months ago
šļø Plasma biomarkers, PET, and MRI ā
@alexapb.bsky.social
explains how these tools are reshaping Alzheimerās diagnostics in the
@istaart.bsky.social
Neuroimaging PIA. Listen now or Watch the last episode in this series. Watch:
youtu.be/x2ifaepExB0
Listen:
pod.fo/e/2fde7c
loading . . .
Neuroimaging PIA - RELAY Video Podcast
YouTube video by Dementia Researcher
https://youtu.be/x2ifaepExB0
0
2
2
reposted by
Ken Covinsky
about 1 year ago
I strongly support the NIH Diversity Supplement Program. Addressing the severe lack of diversity among biomedical researchers improves the quality of research. It's not a level playing field. This program helps restore equity through mentored training. Rescinding this program is a big mistake
0
72
16
www.nature.com/articles/d41...
Iāve been trying to not get worked up with every crazy thing that has happened with the election, but this is likely something to worry about. Really shows how an unserious person Trump is.
loading . . .
āNever seen anything like thisā: Trumpās team halts NIH meetings and travel
In an unprecedented move, research-grant reviews have been suspended indefinitely at the worldās largest public funder of biomedical research.
https://www.nature.com/articles/d41586-025-00231-y
about 1 year ago
0
1
1
Are my kids the only ones who find the winter solstice the IDEAL time to play with water balloons?
about 1 year ago
0
0
0
New preprint out: using data from DIAN, we estimate what sample sizes would be needed for various biomarker outcomes in clinical trials of autosomal dominant Alzheimer's disease:
www.medrxiv.org/content/10.1...
loading . . .
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimerās disease
INTRODUCTION Alzheimer disease (AD)-modifying therapies are approved for treatment of early-symptomatic AD. Autosomal dominant AD (ADAD) provides a unique opportunity to test therapies in presymptomat...
https://www.medrxiv.org/content/10.1101/2024.11.12.24316919v3
about 1 year ago
0
2
0
you reached the end!!
feeds!
log in
